{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T17:44:13Z","timestamp":1759772653278,"version":"3.37.3"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s11033-022-08110-9","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T19:35:49Z","timestamp":1669923349000},"page":"1765-1784","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1643-2011","authenticated-orcid":false,"suffix":"IV","given":"Halford","family":"Warlick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lexie","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudresh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Filoramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Knipe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Joubran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkene","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"8110_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1021\/cn5000056","volume":"5","author":"NE Calcaterra","year":"2014","unstructured":"Calcaterra NE, Barrow JC (2014) Classics in chemical neuroscience: DZP (valium). ACS Chem Neurosci 5:253\u2013260. https:\/\/doi.org\/10.1021\/cn5000056","journal-title":"ACS Chem Neurosci"},{"key":"8110_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000506868","volume":"89","author":"F Cosci","year":"2020","unstructured":"Cosci F, Chouinard G (2020) Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 89:283\u2013306. https:\/\/doi.org\/10.1159\/000506868","journal-title":"Psychother Psychosom"},{"key":"8110_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-015-0493-y","author":"M Liebrenz","year":"2015","unstructured":"Liebrenz M, Gehring MT, Buadze A, Caflisch C (2015) High-dose benzodiazepine dependence: a qualitative study of patients\u2019 perception on cessation and withdrawal. BMC Psychiatry. https:\/\/doi.org\/10.1186\/s12888-015-0493-y","journal-title":"BMC Psychiatry"},{"key":"8110_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2045125317753340","volume":"8","author":"D Fluyau","year":"2018","unstructured":"Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 8:147\u2013168. https:\/\/doi.org\/10.1177\/2045125317753340","journal-title":"Ther Adv Psychopharmacol"},{"key":"8110_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","volume":"38","author":"J Brett","year":"2015","unstructured":"Brett J, Murnion B (2015) Management of benzodiazepine misuse and dependence. Aust Prescr 38:152\u2013155. https:\/\/doi.org\/10.18773\/austprescr.2015.055","journal-title":"Aust Prescr"},{"key":"8110_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","volume":"7","author":"M Lader","year":"1987","unstructured":"Lader M, Olajide D (1987) A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 7:11\u201315","journal-title":"J Clin Psychopharmacol"},{"key":"8110_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6045017","author":"M Markota","year":"2017","unstructured":"Markota M, Morgan RJ (2017) Treatment of generalized anxiety disorder with gabapentin. Case Rep Psychiatry. https:\/\/doi.org\/10.1155\/2017\/6045017","journal-title":"Case Rep Psychiatry"},{"key":"8110_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","volume":"180","author":"RF Anton","year":"2020","unstructured":"Anton RF, Latham P, Voronin K, Book S, Hoffman M, Prisciandaro J, Bristol E (2020) Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med 180:728\u2013736. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0249","journal-title":"JAMA Intern Med"},{"key":"8110_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881111405360","volume":"26","author":"SJ Hadley","year":"2012","unstructured":"Hadley SJ, Mandel FS, Schweizer E (2012) Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 26:461\u2013470. https:\/\/doi.org\/10.1177\/0269881111405360","journal-title":"J Psychopharmacol"},{"unstructured":"Mariani J. Gabapentin treatment of benzodiazepine dependence. ClinicalTrials.gov identifier: NCT01893632. Updated 24 April 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01893632","key":"8110_CR10"},{"key":"8110_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00755","author":"L Liu","year":"2020","unstructured":"Liu L et al (2020) The effects of benzodiazepine use and abuse on cognition in the elders: a systematic review and meta-analysis of comparative studies. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2020.00755","journal-title":"Front Psychiatry"},{"key":"8110_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/jcm7020017","volume":"7","author":"J Guina","year":"2018","unstructured":"Guina J, Merrill B (2018) Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med 7:17. https:\/\/doi.org\/10.3390\/jcm7020017","journal-title":"J Clin Med"},{"key":"8110_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","volume":"559","author":"S Zhu","year":"2018","unstructured":"Zhu S et al (2018) Structure of a human synaptic GABAA receptor. Nature 559:67\u201372. https:\/\/doi.org\/10.1038\/s41586-018-0255-3","journal-title":"Nature"},{"key":"8110_CR14","volume-title":"Stahl\u2019s essential psychopharmacology","author":"SM Stahl","year":"2014","unstructured":"Stahl SM (2014) Stahl\u2019s essential psychopharmacology. Cambridge University Press, Cambridge"},{"key":"8110_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eplepsyres.2009.03.007","volume":"85","author":"MT Bianchi","year":"2009","unstructured":"Bianchi MT et al (2009) Benzodiazepine modulation of GABA(A) receptor opening frequency depends on activation context: a patch clamp and simulation study. Epilepsy Res 85:212\u2013220. https:\/\/doi.org\/10.1016\/j.eplepsyres.2009.03.007","journal-title":"Epilepsy Res"},{"key":"8110_CR16","first-page":"214","volume":"13","author":"CE Griffin","year":"2013","unstructured":"Griffin CE et al (2013) Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 13:214\u2013223","journal-title":"Ochsner J"},{"key":"8110_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrd3502","volume":"10","author":"U Rudolph","year":"2011","unstructured":"Rudolph U, Knoflach F (2011) Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 10:685\u2013697. https:\/\/doi.org\/10.1038\/nrd3502","journal-title":"Nat Rev Drug Discov"},{"key":"8110_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fncir.2014.00003","volume":"8","author":"V Lee","year":"2014","unstructured":"Lee V, Maguire J (2014) The impact of tonic GABAA receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. Front Neural Circuits 8:3. https:\/\/doi.org\/10.3389\/fncir.2014.00003","journal-title":"Front Neural Circuits"},{"key":"8110_CR19","doi-asserted-by":"publisher","first-page":"6464","DOI":"10.1073\/pnas.111055398","volume":"98","author":"I Tobler","year":"2001","unstructured":"Tobler I, Kopp C, Deboer T, Rudolph U (2001) DZP-induced changes in sleep: role of the alpha 1 GABA(A) receptor subtype. Proc Natl Acad Sci USA 98:6464\u20136469. https:\/\/doi.org\/10.1073\/pnas.111055398","journal-title":"Proc Natl Acad Sci USA"},{"key":"8110_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U et al (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401:796\u2013800. https:\/\/doi.org\/10.1038\/44579","journal-title":"Nature"},{"key":"8110_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/75761","volume":"3","author":"RM McKernan","year":"2000","unstructured":"McKernan RM et al (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 3:587\u2013592. https:\/\/doi.org\/10.1038\/75761","journal-title":"Nat Neurosci"},{"key":"8110_CR22","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1523\/JNEUROSCI.1067-04.2004","volume":"24","author":"C van Rijnsoever","year":"2004","unstructured":"van Rijnsoever C et al (2004) Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of DZP in mice. J Neurosci 24:6785\u20136790. https:\/\/doi.org\/10.1523\/JNEUROSCI.1067-04.2004","journal-title":"J Neurosci"},{"key":"8110_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2174\/1568026023393507","volume":"2","author":"W Sieghart","year":"2002","unstructured":"Sieghart W, Sperk G (2002) Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2:795\u2013816. https:\/\/doi.org\/10.2174\/1568026023393507","journal-title":"Curr Top Med Chem"},{"key":"8110_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2008.01.015","volume":"90","author":"CI Dixon","year":"2008","unstructured":"Dixon CI, Rosahl TW, Stephens DN (2008) Targeted deletion of the GABRA2 gene encoding alpha2-subunits of GABA(A) receptors facilitates performance of a conditioned emotional response, and abolishes anxiolytic effects of benzodiazepines and barbiturates. Pharmacol Biochem Behav 90:1\u20138. https:\/\/doi.org\/10.1016\/j.pbb.2008.01.015","journal-title":"Pharmacol Biochem Behav"},{"key":"8110_CR25","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1111\/j.1460-9568.2006.04775.x","volume":"23","author":"HV Morris","year":"2006","unstructured":"Morris HV, Dawson GR, Reynolds DS, Atack JR, Stephens DN (2006) Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Eur J Neurosci 23:2495\u20132504. https:\/\/doi.org\/10.1111\/j.1460-9568.2006.04775.x","journal-title":"Eur J Neurosci"},{"key":"8110_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1126\/science.290.5489.131","volume":"290","author":"K L\u00f6w","year":"2000","unstructured":"L\u00f6w K et al (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131\u2013134. https:\/\/doi.org\/10.1126\/science.290.5489.131","journal-title":"Science"},{"key":"8110_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1124\/mol.59.3.442","volume":"59","author":"F Crestani","year":"2001","unstructured":"Crestani F et al (2001) Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 59:442\u2013445. https:\/\/doi.org\/10.1124\/mol.59.3.442","journal-title":"Mol Pharmacol"},{"key":"8110_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1523\/JNEUROSCI.12-03-01040.1992","volume":"12","author":"W Wisden","year":"1992","unstructured":"Wisden W, Laurie DJ, Monyer H, Seeburg PH (1992) The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 12:1040\u20131062. https:\/\/doi.org\/10.1523\/JNEUROSCI.12-03-01040.1992","journal-title":"J Neurosci"},{"key":"8110_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0169-328x(92)90225-z","volume":"16","author":"JH Zhang","year":"1992","unstructured":"Zhang JH, Sato M, Araki T, Tohyama M (1992) Postnatal ontogenesis of neurons containing GABAA alpha 1 subunit mRNA in the rat forebrain. Brain Res Mol Brain Res 16:193\u2013203. https:\/\/doi.org\/10.1016\/0169-328x(92)90225-z","journal-title":"Brain Res Mol Brain Res"},{"key":"8110_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bjp.0706056","volume":"144","author":"JR Atack","year":"2005","unstructured":"Atack JR et al (2005) Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABAA receptors. Br J Pharmacol 144:357\u2013366. https:\/\/doi.org\/10.1038\/sj.bjp.0706056","journal-title":"Br J Pharmacol"},{"key":"8110_CR31","first-page":"100","volume":"18","author":"JF Navarro","year":"2006","unstructured":"Navarro JF, Bur\u00f3n E, Mart\u00edn-L\u00f3pez M (2006) Anxiolytic-like activity of SB-205384 in the elevated plus-maze test in mice. Psicothema 18:100\u2013104","journal-title":"Psicothema"},{"key":"8110_CR32","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1124\/jpet.105.092320","volume":"316","author":"GR Dawson","year":"2006","unstructured":"Dawson GR et al (2006) An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316:1335\u20131345. https:\/\/doi.org\/10.1124\/jpet.105.092320","journal-title":"J Pharmacol Exp Ther"},{"key":"8110_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/FBP.0b013e3283512c85","volume":"23","author":"M Mili\u0107","year":"2012","unstructured":"Mili\u0107 M et al (2012) The role of \u03b11 and \u03b15 subunit-containing GABAA receptors in motor impairment induced by benzodiazepines in rats. Behav Pharmacol 23:191\u2013197. https:\/\/doi.org\/10.1097\/FBP.0b013e3283512c85","journal-title":"Behav Pharmacol"},{"key":"8110_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00003088-199324060-00003","volume":"24","author":"DJ Greenblatt","year":"1993","unstructured":"Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 24:453\u2013471. https:\/\/doi.org\/10.2165\/00003088-199324060-00003","journal-title":"Clin Pharmacokinet"},{"unstructured":"Basit H, Kahwaji CI (2022) Clonazepam. In: StatPearls. StatPearls Publishing, Treasure Island","key":"8110_CR35"},{"doi-asserted-by":"publisher","unstructured":"Waller DG, Sampson AP (2018) Anxiety, obsessive\u2013compulsive disorder and insomnia. In: Medical pharmacology and therapeutics, 5th edn. pp 282\u2013283. https:\/\/doi.org\/10.1016\/B978-0-7020-7167-6.00020-8","key":"8110_CR36","DOI":"10.1016\/B978-0-7020-7167-6.00020-8"},{"key":"8110_CR37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hup.238","volume":"16","author":"MK Erman","year":"2001","unstructured":"Erman MK et al (2001) Comparative efficacy of zolpidem and temazepam in transient insomnia. Hum Psychopharmacol 16:169\u2013176. https:\/\/doi.org\/10.1002\/hup.238","journal-title":"Hum Psychopharmacol"},{"key":"8110_CR38","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.33549\/physiolres.932678","volume":"63","author":"V Vyklicky","year":"2014","unstructured":"Vyklicky V et al (2014) Structure, function, and pharmacology of NMDA receptor channels. Physiol Res 63:S191\u2013S203. https:\/\/doi.org\/10.33549\/physiolres.932678","journal-title":"Physiol Res"},{"key":"8110_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1196\/annals.1418.005","volume":"1144","author":"MP Mattson","year":"2008","unstructured":"Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 1144:97\u2013112. https:\/\/doi.org\/10.1196\/annals.1418.005","journal-title":"Ann N Y Acad Sci"},{"key":"8110_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.conb.2011.01.001","volume":"21","author":"HY Man","year":"2011","unstructured":"Man HY (2011) GluA2-lacking, calcium-permeable AMPA receptors\u2014inducers of plasticity? Curr Opin Neurobiol 21:291\u2013298. https:\/\/doi.org\/10.1016\/j.conb.2011.01.001","journal-title":"Curr Opin Neurobiol"},{"key":"8110_CR41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN et al (2021) Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int 13:594\u2013607. https:\/\/doi.org\/10.3390\/neurolint13040059","journal-title":"Neurol Int"},{"key":"8110_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/416864","author":"CH Vinkers","year":"2012","unstructured":"Vinkers CH, Olivier B (2012) Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharmacol Sci. https:\/\/doi.org\/10.1155\/2012\/416864","journal-title":"Adv Pharmacol Sci"},{"key":"8110_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bcp.12023","volume":"77","author":"SD Hood","year":"2014","unstructured":"Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK (2014) Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol 77:285\u2013294. https:\/\/doi.org\/10.1111\/bcp.12023","journal-title":"Br J Clin Pharmacol"},{"key":"8110_CR44","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1046\/j.1471-4159.1994.63062349.x","volume":"63","author":"RL Klein","year":"1994","unstructured":"Klein RL, Whiting PJ, Harris RA (1994) Benzodiazepine treatment causes uncoupling of recombinant GABAA receptors expressed in stably transfected cells. J Neurochem 63:2349\u20132352. https:\/\/doi.org\/10.1046\/j.1471-4159.1994.63062349.x","journal-title":"J Neurochem"},{"key":"8110_CR45","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1046\/j.1471-4159.2001.00664.x","volume":"79","author":"NJ Ali","year":"2001","unstructured":"Ali NJ, Olsen RW (2001) Chronic benzodiazepine treatment of cells expressing recombinant GABA(A) receptors uncouples allosteric binding: studies on possible mechanisms. J Neurochem 79:1100\u20131108. https:\/\/doi.org\/10.1046\/j.1471-4159.2001.00664.x","journal-title":"J Neurochem"},{"key":"8110_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.134801","volume":"721","author":"MF Foitzick","year":"2020","unstructured":"Foitzick MF, Medina NB, Iglesias Garc\u00eda LC, Gravielle MC (2020) Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor \u03b11 subunit gene via L-type voltage-gated calcium channel activation in rat cerebrocortical neurons. Neurosci Lett 721:134801. https:\/\/doi.org\/10.1016\/j.neulet.2020.134801","journal-title":"Neurosci Lett"},{"key":"8110_CR47","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41380-018-0100-y","volume":"23","author":"MW Nicholson","year":"2018","unstructured":"Nicholson MW et al (2018) Diazepam-induced loss of inhibitory synapses mediated by PLC\u03b4\/Ca2+\/calcineurin signalling downstream of GABAA receptors. Mol Psychiatry 23:1851\u20131867. https:\/\/doi.org\/10.1038\/s41380-018-0100-y","journal-title":"Mol Psychiatry"},{"key":"8110_CR48","doi-asserted-by":"publisher","first-page":"18595","DOI":"10.1073\/pnas.1204994109","volume":"109","author":"TC Jacob","year":"2012","unstructured":"Jacob TC et al (2012) Benzodiazepine treatment induces subtype-specific changes in GABA(A) receptor trafficking and decreases synaptic inhibition. Proc Natl Acad Sci USA 109:18595\u201318600. https:\/\/doi.org\/10.1073\/pnas.1204994109","journal-title":"Proc Natl Acad Sci USA"},{"key":"8110_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.416","author":"J Auta","year":"2018","unstructured":"Auta J, Gatta E, Davis JM, Pandey SC, Guidotti A (2018) Potential role for histone deacetylation in chronic diazepam-induced downregulation of \u03b11-GABAA receptor subunit expression. Pharmacol Res Perspect. https:\/\/doi.org\/10.1002\/prp2.416","journal-title":"Pharmacol Res Perspect"},{"key":"8110_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF02247359","volume":"112","author":"N Andrews","year":"1993","unstructured":"Andrews N, File SE (1993) Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence. Psychopharmacology 112:21\u201325. https:\/\/doi.org\/10.1007\/BF02247359","journal-title":"Psychopharmacology"},{"key":"8110_CR51","first-page":"310","volume":"103","author":"MB Gupta","year":"1996","unstructured":"Gupta MB, Nath C, Patnaik GK, Saxena RC (1996) Effect of calcium channel blockers on withdrawal syndrome of lorazepam in rats. Indian J Med Res 103:310\u2013314","journal-title":"Indian J Med Res"},{"key":"8110_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.646038","volume":"12","author":"A Benini","year":"2021","unstructured":"Benini A et al (2021) Continuous infusion of flumazenil in the management of benzodiazepines detoxification. Front Psychiatry 12:646038. https:\/\/doi.org\/10.3389\/fpsyt.2021.646038","journal-title":"Front Psychiatry"},{"key":"8110_CR53","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/sj.npp.1300531","volume":"29","author":"BJ Van Sickle","year":"2004","unstructured":"Van Sickle BJ, Xiang K, Tietz EI (2004) Transient plasticity of hippocampal CA1 neuron glutamate receptors contributes to benzodiazepine withdrawal-anxiety. Neuropsychopharmacology 29:1994\u20132006. https:\/\/doi.org\/10.1038\/sj.npp.1300531","journal-title":"Neuropsychopharmacology"},{"key":"8110_CR54","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/FBP.0b013e3282d28f2b","volume":"18","author":"K Xiang","year":"2007","unstructured":"Xiang K, Tietz EI (2007) Benzodiazepine-induced hippocampal CA1 neuron alpha-amino-3-hydroxy-5-methylisoxasole-4-propionic acid (AMPA) receptor plasticity linked to severity of withdrawal anxiety: differential role of voltage-gated calcium channels and N-methyl-d-aspartic acid receptors. Behav Pharmacol 18:447\u2013460. https:\/\/doi.org\/10.1097\/FBP.0b013e3282d28f2b","journal-title":"Behav Pharmacol"},{"key":"8110_CR55","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s12640-017-9810-1","volume":"33","author":"S Talarek","year":"2018","unstructured":"Talarek S, Listos J, Orzelska-Gorka J, Serefko A, Kotli\u0144ska J (2018) NMDA receptors and no:cgmp signaling pathway mediate the DZP-induced sensitization to withdrawal signs in mice. Neurotox Res 33:422\u2013432. https:\/\/doi.org\/10.1007\/s12640-017-9810-1","journal-title":"Neurotox Res"},{"key":"8110_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s43088-021-00125-8","author":"H Rafi","year":"2021","unstructured":"Rafi H, Rafiq H, Farhan M (2021) Inhibition of NMDA receptors by agmatine is followed by GABA\/glutamate balance in benzodiazepine withdrawal syndrome. Beni-Suef Univ J Basic Appl Sci. https:\/\/doi.org\/10.1186\/s43088-021-00125-8","journal-title":"Beni-Suef Univ J Basic Appl Sci"},{"key":"8110_CR57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000139531","volume":"55","author":"JM Koff","year":"1997","unstructured":"Koff JM, Pritchard GA, Greenblatt DJ, Miller LG (1997) The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. Pharmacology 55:217\u2013227. https:\/\/doi.org\/10.1159\/000139531","journal-title":"Pharmacology"},{"key":"8110_CR58","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/sj.npp.1300800","volume":"31","author":"C Allison","year":"2006","unstructured":"Allison C, Pratt JA (2006) Differential effects of two chronic diazepam treatment regimes on withdrawal anxiety and AMPA receptor characteristics. Neuropsychopharmacology 31:602\u2013619. https:\/\/doi.org\/10.1038\/sj.npp.1300800","journal-title":"Neuropsychopharmacology"},{"key":"8110_CR59","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cne.21866","volume":"511","author":"P Das","year":"2008","unstructured":"Das P et al (2008) Increased AMPA receptor GluR1 subunit incorporation in rat hippocampal CA1 synapses during benzodiazepine withdrawal. J Comp Neurol 511:832\u2013846. https:\/\/doi.org\/10.1002\/cne.21866","journal-title":"J Comp Neurol"},{"key":"8110_CR60","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.121402","volume":"11","author":"EY Chen","year":"2021","unstructured":"Chen EY et al (2021) Microgabalin as a novel gabapentinoid for the treatment of chronic pain conditions: an analysis of current evidence. Anesthesiol Pain Med 11:e121402. https:\/\/doi.org\/10.5812\/aapm.121402","journal-title":"Anesthesiol Pain Med"},{"unstructured":"Classification of Phenibut. Phenibut data sheet. January 2018. https:\/\/www.medsafe.govt.nz\/profs\/class\/Agendas\/Agen60\/5.5.1-Phenibut-submission.pdf","key":"8110_CR61"},{"key":"8110_CR62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN et al (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661\u2013669. https:\/\/doi.org\/10.2165\/11536200-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"8110_CR63","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/0091270009352087","volume":"50","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN et al (2010) Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 50:941\u2013950. https:\/\/doi.org\/10.1177\/0091270009352087","journal-title":"J Clin Pharmacol"},{"key":"8110_CR64","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.bcp.2013.03.022","volume":"85","author":"D Dickens","year":"2013","unstructured":"Dickens D et al (2013) Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol 85:1672\u20131683. https:\/\/doi.org\/10.1016\/j.bcp.2013.03.022","journal-title":"Biochem Pharmacol"},{"key":"8110_CR65","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11095-018-2532-0","volume":"35","author":"Y Takahashi","year":"2018","unstructured":"Takahashi Y et al (2018) Transport of pregabalin via L-type amino acid transporter 1 (SLC7A5) in human brain capillary endothelial cell line. Pharm Res 35:246. https:\/\/doi.org\/10.1007\/s11095-018-2532-0","journal-title":"Pharm Res"},{"key":"8110_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706442","author":"AC Dolphin","year":"2006","unstructured":"Dolphin AC (2006) A short history of voltage-gated calcium channels. Br J Pharmacol. https:\/\/doi.org\/10.1038\/sj.bjp.0706442","journal-title":"Br J Pharmacol"},{"key":"8110_CR67","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1113\/JP272262","volume":"594","author":"AC Dolphin","year":"2016","unstructured":"Dolphin AC (2016) Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol 594:5369\u20135390. https:\/\/doi.org\/10.1113\/JP272262","journal-title":"J Physiol"},{"key":"8110_CR68","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003947","volume":"3","author":"WA Catterall","year":"2011","unstructured":"Catterall WA (2011) Voltage-gated calcium channels. Cold Spring Harb Perspect Biol 3:a003947. https:\/\/doi.org\/10.1101\/cshperspect.a003947","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"8110_CR69","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.16104.1","author":"AC Dolphin","year":"2018","unstructured":"Dolphin AC (2018) Voltage-gated calcium channel \u03b12\u03b4 subunits: an assessment of proposed novel roles. F1000Research. https:\/\/doi.org\/10.12688\/f1000research.16104.1","journal-title":"F1000Research"},{"key":"8110_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.205","volume":"4","author":"R Patel","year":"2016","unstructured":"Patel R, Dickenson AH (2016) Mechanisms of the gabapentinoids and \u03b12 \u03b4-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect 4:e00205. https:\/\/doi.org\/10.1002\/prp2.205","journal-title":"Pharmacol Res Perspect"},{"key":"8110_CR71","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1046\/j.1460-9568.2000.01009.x","volume":"12","author":"M Hobom","year":"2000","unstructured":"Hobom M et al (2000) Neuronal distribution and functional characterization of the calcium channel alpha2delta-2 subunit. Eur J Neurosci 12:1217\u20131226. https:\/\/doi.org\/10.1046\/j.1460-9568.2000.01009.x","journal-title":"Eur J Neurosci"},{"key":"8110_CR72","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/j.1532-2149.2013.00416.x","volume":"18","author":"C Zhou","year":"2014","unstructured":"Zhou C, Luo ZD (2014) Electrophysiological characterization of spinal neuron sensitization by elevated calcium channel alpha-2-delta-1 subunit protein. Eur J Pain 18:649\u2013658. https:\/\/doi.org\/10.1002\/j.1532-2149.2013.00416.x","journal-title":"Eur J Pain"},{"key":"8110_CR73","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/bja\/aes120","volume":"109","author":"JH Ryu","year":"2012","unstructured":"Ryu JH, Lee PB, Kim JH, Do SH, Kim CS (2012) Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anesth 109:234\u2013239. https:\/\/doi.org\/10.1093\/bja\/aes120","journal-title":"Br J Anesth"},{"key":"8110_CR74","doi-asserted-by":"publisher","first-page":"12856","DOI":"10.1523\/JNEUROSCI.2700-10.2010","volume":"30","author":"A Tran-Van-Minh","year":"2010","unstructured":"Tran-Van-Minh A, Dolphin AC (2010) The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2. J Neurosci 30:12856\u201312867. https:\/\/doi.org\/10.1523\/JNEUROSCI.2700-10.2010","journal-title":"J Neurosci"},{"key":"8110_CR75","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","volume":"29","author":"CS Bauer","year":"2009","unstructured":"Bauer CS et al (2009) The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J Neurosci 29:4076\u20134088. https:\/\/doi.org\/10.1523\/JNEUROSCI.0356-09.2009","journal-title":"J Neurosci"},{"key":"8110_CR76","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1073\/pnas.0708930105","volume":"105","author":"J Hendrich","year":"2008","unstructured":"Hendrich J et al (2008) Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci USA 105:3628\u20133633. https:\/\/doi.org\/10.1073\/pnas.0708930105","journal-title":"Proc Natl Acad Sci USA"},{"key":"8110_CR77","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s0028-3908(97)00189-5","volume":"37","author":"A Stefani","year":"1998","unstructured":"Stefani A, Spadoni F, Bernardi G (1998) Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 37:83\u201391. https:\/\/doi.org\/10.1016\/s0028-3908(97)00189-5","journal-title":"Neuropharmacology"},{"key":"8110_CR78","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41583-020-0278-2","volume":"21","author":"AC Dolphin","year":"2020","unstructured":"Dolphin AC, Lee A (2020) Presynaptic calcium channels: specialized control of synaptic neurotransmitter release. Nat Rev Neurosci 21:213\u2013229. https:\/\/doi.org\/10.1038\/s41583-020-0278-2","journal-title":"Nat Rev Neurosci"},{"key":"8110_CR79","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/j.1460-9568.2004.03625.x","volume":"20","author":"MO Cunningham","year":"2004","unstructured":"Cunningham MO, Woodhall GL, Thompson SE, Dooley DJ, Jones RS (2004) Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 20:1566\u20131576. https:\/\/doi.org\/10.1111\/j.1460-9568.2004.03625.x","journal-title":"Eur J Neurosci"},{"key":"8110_CR80","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/s1059-1311(02)00295-9","volume":"12","author":"LD Errante","year":"2003","unstructured":"Errante LD, Petroff OA (2003) Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 12:300\u2013306. https:\/\/doi.org\/10.1016\/s1059-1311(02)00295-9","journal-title":"Seizure"},{"key":"8110_CR81","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.mehy.2006.06.014","volume":"68","author":"J Gazulla","year":"2007","unstructured":"Gazulla J, Tintor\u00e9 MA (2007) The P\/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: gabapentin and pregabalin may be of therapeutic benefit. Med Hypotheses 68:131\u2013136. https:\/\/doi.org\/10.1016\/j.mehy.2006.06.014","journal-title":"Med Hypotheses"},{"key":"8110_CR82","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neuropharm.2003.11.010","volume":"46","author":"K Bayer","year":"2004","unstructured":"Bayer K, Ahmadi S, Zeilhofer HU (2004) Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P\/Q-type Ca2+ channels. Neuropharmacology 46:743\u2013749. https:\/\/doi.org\/10.1016\/j.neuropharm.2003.11.010","journal-title":"Neuropharmacology"},{"key":"8110_CR83","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/sj.bjp.0703380","volume":"130","author":"K Fink","year":"2000","unstructured":"Fink K, Meder W, Dooley DJ, G\u00f6thert M (2000) Inhibition of neuronal Ca(2+) influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices. Br J Pharmacol 130:900\u2013906. https:\/\/doi.org\/10.1038\/sj.bjp.0703380","journal-title":"Br J Pharmacol"},{"key":"8110_CR84","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/syn.20115","volume":"55","author":"JT Brown","year":"2005","unstructured":"Brown JT, Randall A (2005) Gabapentin fails to alter P\/Q-type Ca2+ channel-mediated synaptic transmission in the hippocampus in vitro. Synapse 55:262\u2013269. https:\/\/doi.org\/10.1002\/syn.20115","journal-title":"Synapse"},{"key":"8110_CR85","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1124\/jpet.110.178384","volume":"338","author":"JE Quintero","year":"2011","unstructured":"Quintero JE, Dooley DJ, Pomerleau F, Huettl P, Gerhardt GA (2011) Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: role of voltage-sensitive Ca2+ \u03b12\u03b4-1 subunit. J Pharmacol Exp Ther 338:240\u2013245. https:\/\/doi.org\/10.1124\/jpet.110.178384","journal-title":"J Pharmacol Exp Ther"},{"key":"8110_CR86","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fpsyt.2018.00078","volume":"9","author":"DJ Meyerhoff","year":"2018","unstructured":"Meyerhoff DJ, Murray DE, Durazzo TC, Pennington DL (2018) Brain GABA and glutamate concentrations following chronic gabapentin administration: a convenience sample studied during early abstinence from alcohol. Front Psychiatry 9:78. https:\/\/doi.org\/10.3389\/fpsyt.2018.00078","journal-title":"Front Psychiatry"},{"key":"8110_CR87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/s-2007-1014645","volume":"21","author":"W Haefely","year":"1988","unstructured":"Haefely W (1988) Endogenous ligands of the benzodiazepine receptor. Pharmacopsychiatry 21:43\u201346. https:\/\/doi.org\/10.1055\/s-2007-1014645","journal-title":"Pharmacopsychiatry"},{"key":"8110_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.06.008","volume":"208","author":"MC Tonon","year":"2020","unstructured":"Tonon MC et al (2020) Endozepines and their receptors: structure, functions and pathophysiological significance. Pharmacol Ther 208:107386. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.06.008","journal-title":"Pharmacol Ther"},{"key":"8110_CR89","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/bs.apha.2014.10.005","volume":"72","author":"Z Farzampour","year":"2015","unstructured":"Farzampour Z, Reimer RJ, Huguenard J (2015) Endozepines. Adv Pharmacol 72:147\u2013164. https:\/\/doi.org\/10.1016\/bs.apha.2014.10.005","journal-title":"Adv Pharmacol"},{"key":"8110_CR90","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s11434-016-1136-5","volume":"61","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen XY, Martin C (2016) Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Sci Bull 61:1391\u20131398. https:\/\/doi.org\/10.1007\/s11434-016-1136-5","journal-title":"Sci Bull"},{"key":"8110_CR91","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/JEP.S23105","volume":"4","author":"C Wasowski","year":"2012","unstructured":"Wasowski C, Marder M (2012) Flavonoids as GABAA receptor ligands: the whole story. J Exp Pharmacol 4:9\u201324. https:\/\/doi.org\/10.2147\/JEP.S23105","journal-title":"J Exp Pharmacol"},{"key":"8110_CR92","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/brainsci8060104","volume":"8","author":"K Sowndhararajan","year":"2018","unstructured":"Sowndhararajan K, Deepa P, Kim M, Park SJ, Kim S (2018) Neuroprotective and cognitive enhancement potentials of baicalin: a review. Brain Sci 8:104. https:\/\/doi.org\/10.3390\/brainsci8060104","journal-title":"Brain Sci"},{"key":"8110_CR93","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.3892\/etm.2019.7469","volume":"17","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, La JH, Kim HM, Yang IS, Sung TS (2019) Anti-diarrheal effect of Scutellaria baicalensis is associated with suppression of smooth muscle in the rat colon. Exp Ther Med 17:4748\u20134756. https:\/\/doi.org\/10.3892\/etm.2019.7469","journal-title":"Exp Ther Med"},{"key":"8110_CR94","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12906-017-1776-2","volume":"17","author":"BY Choi","year":"2017","unstructured":"Choi BY et al (2017) Anti-cancer effect of Scutellaria baicalensis in combination with cisplatin in human ovarian cancer cell. BMC Complement Altern Med 17:277. https:\/\/doi.org\/10.1186\/s12906-017-1776-2","journal-title":"BMC Complement Altern Med"},{"key":"8110_CR95","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1055\/s-0029-1243121","volume":"66","author":"KM Hui","year":"2000","unstructured":"Hui KM, Wang XH, Xue H (2000) Interaction of flavones from the roots of Scutellaria baicalensis with the benzodiazepine site. Planta Med 66:91\u201393. https:\/\/doi.org\/10.1055\/s-0029-1243121","journal-title":"Planta Med"},{"key":"8110_CR96","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/s0006-2952(02)01347-3","volume":"64","author":"KM Hui","year":"2002","unstructured":"Hui KM et al (2002) Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol 64:1415\u20131424. https:\/\/doi.org\/10.1016\/s0006-2952(02)01347-3","journal-title":"Biochem Pharmacol"},{"key":"8110_CR97","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/459549","volume":"2014","author":"J Yang","year":"2014","unstructured":"Yang J, Wu X, Yu H, Liao X, Teng L (2014) NMDA receptor-mediated neuroprotective effect of the Scutellaria baicalensis Georgi extract on the excitotoxic neuronal cell death in primary rat cortical cell cultures. Sci World J 2014:459549. https:\/\/doi.org\/10.1155\/2014\/459549","journal-title":"Sci World J"},{"key":"8110_CR98","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2012.08.006","volume":"136","author":"E Engin","year":"2012","unstructured":"Engin E, Liu J, Rudolph U (2012) \u03b12-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders. Pharmacol Ther 136:142\u2013152. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.08.006","journal-title":"Pharmacol Ther"},{"key":"8110_CR99","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00213-005-0119-z","volume":"182","author":"L Mathiasen","year":"2005","unstructured":"Mathiasen L, Mirza NR (2005) A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test. Psychopharmacology 182:475\u2013484. https:\/\/doi.org\/10.1007\/s00213-005-0119-z","journal-title":"Psychopharmacology"},{"key":"8110_CR100","first-page":"890","volume":"31","author":"Z Gong","year":"2011","unstructured":"Gong Z, Xiong YC (2011) Effect of L-838,417 on pain behavior in a rat model of trigeminal neuralgia. J South Med Univ 31:890\u2013893","journal-title":"J South Med Univ"},{"key":"8110_CR101","first-page":"15","volume":"64","author":"GG Neznamov","year":"2001","unstructured":"Neznamov GG, Siuniakov SA, Chumakov DV, Bochkarev VK, Seredenin SB (2001) Clinical study of the selective anxiolytic agent afobazol. Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian] 64:15\u201319","journal-title":"Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian]"},{"key":"8110_CR102","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10517-009-0624-x","volume":"148","author":"SB Seredenin","year":"2009","unstructured":"Seredenin SB, Antipova TA, Voronin MV, Kurchashova SY, Kuimov AN (2009) Interaction of afobazole with sigma1-receptors. Bull Exp Biol Med 148:42\u201344. https:\/\/doi.org\/10.1007\/s10517-009-0624-x","journal-title":"Bull Exp Biol Med"},{"key":"8110_CR103","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3390\/ijms22115455","volume":"22","author":"MV Voronin","year":"2021","unstructured":"Voronin MV et al (2021) Involvement of chaperone Sigma1R in the anxiolytic effect of fabomotizole. Int J Mol Sci 22:5455. https:\/\/doi.org\/10.3390\/ijms22115455","journal-title":"Int J Mol Sci"},{"key":"8110_CR104","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10517-021-05168-6","volume":"171","author":"SA Kryzhanovskii","year":"2021","unstructured":"Kryzhanovskii SA et al (2021) On the mechanism of cardioprotective effect of fabomotizole in alcoholic cardiomyopathy. Bull Exp Biol Med 171:41\u201344. https:\/\/doi.org\/10.1007\/s10517-021-05168-6","journal-title":"Bull Exp Biol Med"},{"key":"8110_CR105","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10517-019-04586-x","volume":"167","author":"IB Tsorin","year":"2019","unstructured":"Tsorin IB, Barchukov VV, Vititnova MB, Kryzhanovskii SA, Seredenin SB (2019) Anti-ischemic activity of fabomotizole hydrochloride under conditions of endothelial dysfunction. Bull Exp Biol Med 167:634\u2013636. https:\/\/doi.org\/10.1007\/s10517-019-04586-x","journal-title":"Bull Exp Biol Med"},{"key":"8110_CR106","first-page":"12","volume":"72","author":"TA Antipova","year":"2009","unstructured":"Antipova TA, Sapozhnikova DS, Bakhtina L, Seredenin SB (2009) Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons. Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian] 72:12\u201314","journal-title":"Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian]"},{"key":"8110_CR107","first-page":"6","volume":"77","author":"LG Kolik","year":"2014","unstructured":"Kolik LG et al (2014) Assessment of afobazole effects on DZP withdrawal-induced anxiety in rats. Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian] 77:6\u20139","journal-title":"Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian]"},{"key":"8110_CR108","doi-asserted-by":"publisher","first-page":"73","DOI":"10.17116\/terarkh201688873-86","volume":"88","author":"TS Syunyakov","year":"2016","unstructured":"Syunyakov TS, Neznamov GG (2016) Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: results of a multicenter randomized comparative study of DZP. Terapevticheskii arkhiv [Russian] 88:73\u201386. https:\/\/doi.org\/10.17116\/terarkh201688873-86","journal-title":"Terapevticheskii arkhiv [Russian]"},{"key":"8110_CR109","first-page":"6","volume":"73","author":"MA Reutova","year":"2010","unstructured":"Reutova MA, Siuniakov SA, Siuniakov TS, Neznamov GG (2010) Anxiolytic afobazole action self-evaluated by patients with anxiety-asthenic disorders. Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian] 73:6\u201312","journal-title":"Eksperimental\u2019naia i klinicheskaia farmakologiia [Russian]"},{"key":"8110_CR110","doi-asserted-by":"publisher","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","volume":"6","author":"A Schmitz","year":"2016","unstructured":"Schmitz A (2016) Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin 6:120\u2013126. https:\/\/doi.org\/10.9740\/mhc.2016.05.120","journal-title":"Ment Health Clin"},{"key":"8110_CR111","doi-asserted-by":"publisher","first-page":"10445","DOI":"10.1038\/s41598-020-67318-6","volume":"10","author":"YS Althobaiti","year":"2020","unstructured":"Althobaiti YS et al (2020) Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system. Sci Rep 10:10445. https:\/\/doi.org\/10.1038\/s41598-020-67318-6","journal-title":"Sci Rep"},{"key":"8110_CR112","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL (2016) Gabapentin misuse, abuse and diversion: a systematic review. Addiction 111:1160\u20131174. https:\/\/doi.org\/10.1111\/add.13324","journal-title":"Addiction"},{"key":"8110_CR113","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","volume":"172","author":"RV Smith","year":"2015","unstructured":"Smith RV, Lofwall MR, Havens JR (2015) Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian, Kentucky. Am J Psychiatry 172:487\u2013488. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14101272","journal-title":"Am J Psychiatry"},{"key":"8110_CR114","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40264-020-00985-6","volume":"43","author":"S H\u00e4gg","year":"2020","unstructured":"H\u00e4gg S, J\u00f6nsson AK, Ahlner J (2020) Current evidence on abuse and misuse of gabapentinoids. Drug Saf 43:1235\u20131254. https:\/\/doi.org\/10.1007\/s40264-020-00985-6","journal-title":"Drug Saf"},{"key":"8110_CR115","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1073\/pnas.0405621102","volume":"102","author":"JK Rowlett","year":"2005","unstructured":"Rowlett JK et al (2005) Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci USA 102:915\u2013920. https:\/\/doi.org\/10.1073\/pnas.0405621102","journal-title":"Proc Natl Acad Sci USA"},{"key":"8110_CR116","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/phar.2309","volume":"39","author":"AR Levine","year":"2019","unstructured":"Levine AR et al (2019) High-dose gabapentin for the treatment of severe alcohol withdrawal syndrome: a retrospective cohort analysis. Pharmacotherapy 39:881\u2013888. https:\/\/doi.org\/10.1002\/phar.2309","journal-title":"Pharmacotherapy"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-022-08110-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-022-08110-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T17:57:40Z","timestamp":1675187860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-022-08110-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["8110"],"URL":"https:\/\/doi.org\/10.1007\/s11033-022-08110-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies, including human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or animal participants"}}]}}